Recombitope peptides
    1.
    发明授权
    Recombitope peptides 失效
    重组单抗肽

    公开(公告)号:US07211408B2

    公开(公告)日:2007-05-01

    申请号:US10463113

    申请日:2003-06-16

    IPC分类号: G01N33/00 C12N15/09 C07K1/00

    摘要: The present invention provides peptides having T cell stimulating activity termed recombitope peptides. Recombitope peptides of the invention preferably comprise at least two T cell epitopes derived from the same or from different protein antigens, and more preferably comprise at least two regions, each region preferably having human T cell stimulating activity and each region comprising at least one T cell epitope derived from a protein antigen. Recombitope peptides of the invention can be derived from protein allergens, autoantigens, or other protein antigens. The invention also provides methods of diagnosing sensitivity to a protein allergen or other protein antigen in an individual, methods to treat such sensitivity and therapeutic compositions comprising one or more recombitope peptides. The invention further provides methods for designing recombitope peptides of the invention where the protein antigen to which the individual is sensitive has unknown or ill-defined T cell epitopes.

    摘要翻译: 本发明提供了称为重组竞争肽的具有T细胞刺激活性的肽。 本发明的重组匹配肽优选包含至少两种衍生自相同或不同蛋白质抗原的T细胞表位,更优选包含至少两个区域,每个区域优选具有人T细胞刺激活性,每个区域包含至少一个T细胞 衍生自蛋白质抗原的表位。 本发明的重组蛋白多肽可以衍生自蛋白质过敏原,自身抗原或其他蛋白质抗原。 本发明还提供诊断个体中蛋白质变应原或其他蛋白质抗原的敏感性的方法,治疗这种敏感性的方法和包含一种或多种重组蛋白多肽的治疗组合物的方法。 本发明还提供了用于设计本发明的重组蛋白肽的方法,其中个体敏感的蛋白质抗原具有未知或不明确的T细胞表位。

    Allergenic proteins and peptides from Japanese cedar pollen
    2.
    发明授权
    Allergenic proteins and peptides from Japanese cedar pollen 有权
    来自日本雪松花粉的过敏蛋白和肽

    公开(公告)号:US08540999B2

    公开(公告)日:2013-09-24

    申请号:US10931260

    申请日:2004-08-30

    摘要: The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of treatment or of diagnosis of sensitivity to Japanese cedar pollens in an individual and therapeutic compositions, and multipeptide formulations comprising one or more peptides of the invention are also provided.

    摘要翻译: 本发明提供了编码粳稻主要花粉过敏原Cryj I,Cryj II,Jun s I和Jun v I的核酸序列及其片段或肽。 本发明还提供纯化的Cry j I,Cryj II,Jun s I和Jun v I,以及在用编码Cryj I,Cryj II,Jun的核酸序列转化的宿主细胞中产生的至少一个片段 I和Jun v I或其至少一个片段,以及Cry j I,Cry j II,Jun s I或Jun v I或其至少一个片段的片段,以及Cryj I,Cryj II,Jun 我或Jun v我合成了。 Cry j I,Cry j II,Jun s I和Jun v I及其片段可用于诊断,治疗和预防日本雪松花粉病。 本发明还提供了Cryj I和Cryj II的分离的肽。 本发明范围内的肽包含至少一个T细胞表位,或优选至少两个Cryj I或Cryj II的T细胞表位。 本发明还涉及与相应的天然存在的变应原或其部分具有相似或增强的治疗性质但具有减少的副作用的改性肽。 还提供了治疗或诊断个体对日本雪松花粉和治疗组合物的方法,以及包含一种或多种本发明的肽的多肽制剂。

    Chemically Modified Small Molecules
    8.
    发明申请
    Chemically Modified Small Molecules 有权
    化学改性的小分子

    公开(公告)号:US20100210676A1

    公开(公告)日:2010-08-19

    申请号:US12710167

    申请日:2010-02-22

    IPC分类号: A61K31/485 A61P25/36

    摘要: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.

    摘要翻译: 通过肺途径改变施用于受试者的药物的全身吸收速率的方法,所述方法包括将亲水性聚合物与药物共价共轭,其中所述药物具有从肺中消除的半衰期小于约180 分钟,以形成药物 - 聚合物缀合物,其中药物 - 聚合物缀合物具有净亲水特性和约50至约20,000道尔顿的重均分子量,并且其中从药物的肺中消除的半衰期 - 聚合物缀合物比从药物肺消除的半衰期大至少约1.5倍,其中通过支气管肺泡灌洗测量肺部消除的半衰期,然后测定残留的肺部材料。

    MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE
    10.
    发明申请
    MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE 审中-公开
    改性治疗肽,其制备和使用方法

    公开(公告)号:US20110171312A1

    公开(公告)日:2011-07-14

    申请号:US13119208

    申请日:2009-09-17

    摘要: Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms.

    摘要翻译: 修饰的治疗性肽组合物包含与一种或多种亲水性聚合物共价偶联的治疗性肽的缀合物。 任选地,治疗性肽还共价偶联至一个或多个具有1-10个碳原子的部分。 还提供了制作和使用的方法。 缀合物当通过许多给药途径中的任一种施用时,显示出与未附着于水溶性低聚物和/或具有1-10个碳原子的一个或多个部分的肽的特征不同的特征。